BMS-986288 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BMS-986288’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BMS-986288 is under development for the treatment of advanced solid tumors including head and neck cancer squamous cell carcinoma, non-small cell lung cancer, melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma, transitional cell carcinoma (urothelial cell carcinoma), gastric cancer, esophageal cancer, cervical cancer, and colorectal cancer. It is being developed based on a modified version of ipilimumab. The drug candidate targets CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4). The drug candidate is designed using the Probody platform. Probodies are fully recombinant, masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
For a complete picture of BMS-986288’s drug-specific PTSR and LoA scores, buy the report here.